Gastrointestinal symptoms, affecting 80%, include abdominal pain and bloating, necessitating lifestyle and dietary adjustments
Wegovy is administered as a once-weekly subcutaneous injection, with dosing gradually escalated over 16-20 weeks to minimise gastrointestinal side effects
Diet and exercise are the two most important factors in losing weight and supporting overall health
It has been the subject of extensive preclinical research examining its cytoprotective, angiogenic, and regenerative properties across multiple tissue systems
The cohort was somewhat diverse: 74.9% were White, 18.2% were Black, 7.1% had Hispanic ethnicity, 1% were Asian, and 3.5% were of other races